Cargando…
A Gene Panel for Early Identification of Future Responders to Immune Checkpoint Blockade
Immune checkpoint blockade (ICB), therapies that target the PD-1 pathway, CTLA-4 pathway, and other checkpoint pathways, lead to durable responses in many cancer types. Since only a minority of patients respond to ICB, it may be useful to identify the future responders early in the course of treatme...
Autores principales: | Panda, Anshuman, Betigeri, Anil, Ganesan, Shridar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928072/ https://www.ncbi.nlm.nih.gov/pubmed/35309122 http://dx.doi.org/10.3389/fgene.2022.706468 |
Ejemplares similares
-
Genomic and Immunologic Correlates of Indoleamine 2,3-Dioxygenase Pathway Expression in Cancer
por: Panda, Anshuman, et al.
Publicado: (2021) -
Gene Expression in Barrett’s Esophagus Cell Lines Resemble Esophageal Squamous Cell Carcinoma Instead of Esophageal Adenocarcinoma
por: Panda, Anshuman, et al.
Publicado: (2021) -
The Predictive Role of Immune Related Subgroup Classification in Immune Checkpoint Blockade Therapy for Lung Adenocarcinoma
por: Yu, Xiaozhou, et al.
Publicado: (2021) -
Utilization of hypoxia-derived gene signatures to predict clinical outcomes and immune checkpoint blockade therapy responses in prostate cancer
por: Chen, Minhua, et al.
Publicado: (2022) -
Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
por: Cai, Xin, et al.
Publicado: (2021)